RVPH — Reviva Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00Brief: Reviva Announces Last Patient Evaluated In Pivotal Phase 3 Recover Trial For Brilaroxazine In Schizophrenia
Brief: Reviva Announces Enrollment Completion For Pivotal Phase 3 Recover Study For Brilaroxazine In Schizophrenia
Brief: Reviva Pharmaceuticals Q2 net income USD -12.4 million
Reviva Pharmaceuticals Holdings, Inc. reports results for the quarter ended in June - Earnings Summary
Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 28 cents a share - Earnings Preview
Brief: Reviva Pharmaceuticals To Be Added To Russell Microcap Index
U.S. STOCKS ON THE MOVE-NRG Energy, GMS, Dow
Reviva Pharma up on enrollment updates in late-stage schizophrenia drug trial
Brief: Reviva Pharmaceuticals Announces 80% Global Enrollment Update For Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine For Schizophrenia
U.S. STOCKS ON THE MOVE-Ralph Lauren, American Airlines, Illumina
U.S. STOCKS ON THE MOVE-NVIDIA, e.l.f. Beauty, Dish Network
U.S. STOCKS ON THE MOVE-Chipmakers, Best Buy, Nutanix
Reviva rises on positive lung disease treatment data in animal study
Brief: Reviva Pharmaceuticals Announced Preclinical Efficacy Data On Brilaroxazine In Ipf, U.S. FDA Granted 'Orphan Drug' Designation
Brief: Reviva Pharmaceuticals Reports First Quarter 2023 Results
Reviva Pharmaceuticals Holdings, Inc. reports results for the quarter ended in March - Earnings Summary
Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 32 cents a share - Earnings Preview
Brief: Reviva Pharmaceuticals Announces Intent To File An IND For Brilaroxazine In Psoriasis After Promising Preclinical Data
Brief: Reviva Pharmaceuticals Holdings Inc Says Topline Data From Phase 3 Recover Trial For Brilaroxazine Inschizophrenia Expected Mid-2023